お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
347928

慢性閉塞性肺疾患 (COPD) - 疫学的予測

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

出版日: | 発行: GlobalData | ページ情報: 英文 38 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.78円
慢性閉塞性肺疾患 (COPD) - 疫学的予測
出版日: 2019年12月31日
発行: GlobalData
ページ情報: 英文 38 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートでは、慢性閉塞性肺疾患の概要とリスクファクター、世界8大市場における動向とともに、今後の疫学的予測をまとめています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスクファクターと併存疾患
  • 世界的動向
    • 米国
    • 欧州5か国
    • 日本およびオーストラリア
  • 予測方法
    • 用いた情報源
    • 用いなかった情報源
    • 予測方法と仮説
  • 疫学的予測
    • 罹患件数
    • 年齢別罹患件数
    • 性別罹患件数
    • 年齢標準化件数
    • 重度別件数
    • 診断済み件数
    • 年齢別診断済み件数
    • 性別診断済み件数
    • 年齢評価診断済み件数
    • 重度別診断済み件数
    • 併存疾患のある診断済み件数
    • 1年生存の診断済み件数
  • 考察
    • 疫学的予測
    • 分析の限界
    • 分析の強み

第4章 付録

図表

図表

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for COPD

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years, 2018 and 2028
  • Figure 2: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years, 2018 and 2028
  • Figure 3: 7MM, Total Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 4: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 5: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
  • Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
  • Figure 8: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 9: 7MM, Total Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 10: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 11: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 12: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 13: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 14: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 15: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 16: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
目次
Product Code: GDHCER228-19

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms. The disease is diagnosed based on symptoms and the results of spirometry testing, which measures how deeply a person breathes and how fast air moves in and out of the lungs (World Health Organization, 2017). Spirometry results can also be used to determine the severity of COPD. The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for COPD was based on symptoms and the results of spirometry testing. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. GlobalData epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in GlobalData's forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Scope

  • The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages ≥35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
  • The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Obstructive Pulmonary Disease Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
  • Understand magnitude of COPD population by severity at diagnosis.

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Chronic Obstructive Pulmonary Disease (COPD): Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for COPD (2018-2028)
    • 3.5.1 Total Prevalent Cases of COPD
    • 3.5.2 Sex-Specific Total Prevalent Cases of COPD
    • 3.5.3 Age-Specific Total Prevalent Cases of COPD
    • 3.5.4 Diagnosed Prevalent Cases of COPD
    • 3.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.7 Diagnosed Prevalent Cases of COPD by Severity
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.